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Abstract 
Multiple myeloma (MM), an incurable plasma cell malignancy, requires localisation within the bone 
marrow. This microenvironment facilitates crucial interactions between the cancer cells and stromal 
cell types that permit the tumour to survival and proliferate. There is increasing evidence that the 
bone marrow mesenchymal stem cell (BMMSC) is stably altered in patients with MM – a phenotype 
also postulated to exist in patients with monoclonal gammopathy of undetermined significance 
(MGUS) a benign condition that precedes MM. In this study, we describe a mechanism by which 
increased expression of peptidyl arginine deiminase 2 (PADI2) by BMMSCs in patients with MGUS 
and MM directly alters malignant plasma cell phenotype. We identify PADI2 as one of the most 
highly upregulated transcripts in BMMSCs from both MGUS and MM patients, and that through its 
enzymatic deimination of histone H3 arginine 26, PADI2 activity directly induces the upregulation of 
interleukin-6 (IL-6) expression. This leads to the acquisition of resistance to the chemotherapeutic 
agent, bortezomib, by malignant plasma cells. We therefore describe a novel mechanism by which 
BMMSC dysfunction in patients with MGUS and MM directly leads to pro-malignancy signalling 
through the citrullination of histone H3R26. 
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Introduction 
Multiple myeloma (MM) is a malignant disease of plasma cells within the bone marrow that, 
despite improving survival, remains incurable meaning an urgent requirement for novel 
therapies. One characteristic feature of MM is that a pre-malignant condition known as 
monoclonal gammopathy of undetermined significance (MGUS) can be present for many 
years prior to development of overt disease(1). No specific genetic alterations have yet been 
identified that distinguish patients with MGUS from those with MM, suggesting that another 
factor, such as transformation of the microenvironment are likely drivers of progression(2, 3). 
Malignant plasma cells have an absolute requirement for localisation within the bone marrow 
niche, which leads to a characteristic feature of MM: the relative rarity of disease metastasis 
to sites outside the marrow microenvironment. This suggests that, in common with most 
malignancies, stromal support of cancer cell survival in MM is important for maintaining and 
even driving disease(4-6).  
Key cellular components of both the normal and transformed bone marrow niche are the 
bone marrow mesenchymal stromal cells (BMMSCs). There is now significant evidence to 
suggest that BMMSCs from patients with MM(7-11) and MGUS(7) are phenotypically 
different from those derived from healthy patients. Indeed they have not only been shown to 
exhibit a stably altered transcriptional profile(7), but may also contain a number of genetic 
lesions(12). The phenotypic changes resulting from this altered transcriptome appear to 
permit increased stromal support of the malignant plasma cell, and decreased osteoblastic 
differentiated function (bone mineralisation)(7-11). The former is through both physical (i.e. 
cell-cell) interactions, and secretion of a number of paracrine factors that support malignant 
plasma cell survival, proliferation migration and chemoresistance(5, 6, 13). Although a 
number of signaling pathways have been implicated in the differentiation of BMMSCs there 
remains a lack of clarity as to their role.  
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A number of cytokines and chemokines have been shown to be involved in the crosstalk 
between the bone marrow stroma and malignant plasma cells, including interleukin-6 (IL-
6)(14), C-X-C motif chemokine 12 (CXCL12, also known as Stromal-Derived Factor 1 
[SDF1])(15), Vascular Endothelial Growth Factor (VEGF)(16), fibroblast growth factor 
(FGF)(17), tumour necrosis factor α (TNFα)(18), interleukin-1β (IL-1β)(18) and cMET (also 
known as Hepatocyte Growth Factor/Scatter Factor (HGF/SF)(19). IL-6 secretion by the cells 
of bone marrow microenvironment, especially the BMMSC population(7, 9, 11), has been 
shown to play a role in malignant plasma cell phenotype through increasing resistance to cell 
death stimuli and driving proliferation(20), as well as downregulating differentiation markers, 
such as CD38 and CD138(21). It is therefore now clear that through both physical 
association and paracrine interactions, signaling between BMMSCs and myeloma cells 
underlie the requirement of myeloma cells for BM localization.  
One defining feature of BMMSCs isolated from patient bone marrows is that they retain a 
transcriptomic profile despite being in culture(7-9, 11, 21). This suggests that they sustain 
this transcriptome through a stable genetic and/or epigenetic profile. Interestingly, little is 
known about the epigenetic status of BMMSCs in healthy individuals or of those from MGUS 
or MM patients. A post-translational modification in which there is increasing interest in both 
cancer and inflammation is the citrullination of peptidyl arginine, which can occur on many 
different protein species, including histones(22). These reactions are performed by the 
calcium-dependent peptidyl arginine deiminase (PADI) family of enzymes of which there are 
five members (PADI1, 2, 3, 4 and 6) with tissue-specific expression patterns(23-25). PADI2 
is ubiquitously expressed, and in many tissues has been reported as the major family 
member providing peptidyl arginine deiminase activity(26). Importantly, both PADI2 and 
PADI4 have been shown to be able to alter gene transcription through the citrullination of 
residues in the histone tails(27-29): a modification that may be physiologically irreversible 
due to the lack of any known peptidylcitrulline imidating enzyme. This modification is 
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therefore a good candidate for the creation of a long-term change in the cellular 
transcriptome, as noted in the BMMSCs of MM patients.  
As MM is effectively incurable, and is now accepted to almost always arise from MGUS(1), 
the phenotype of cells contributing to this benign condition may provide important clues as to 
factors determining progression to MM. We show here that BMMSCs from patients with both 
MGUS and MM exhibit a significant shift in their transcriptome compared to those from 
healthy individuals. In addition, we demonstrate that one of the most upregulated transcripts 
in BM-MSCs from MGUS and MM, peptidyl arginine deiminase 2 (PADI2) is responsible for 
mediating increased IL-6 expression from these cells through the deimination of arginine 
residue 26 of histone H3 (H3R26) to form citrulline (H3R26cit). This increased IL-6 
production is sufficient to drive resistance of malignant plasma cells to bortezomib (BTM), a 
highly clinically relevant anti-myeloma drug. We therefore demonstrate a novel mechanism 
for BM microenvironment-induced acquisition of drug resistance in MM and importantly, that 
this phenotype is already present in patients with the apparently benign MGUS.  
 
Methods 
Patient sample collection, BMMSC isolation and cell culture 
Patients with MM and MGUS were recruited from specialist clinics at The Royal 
Wolverhampton Hospitals NHS Trust and Heart of England NHS Trust, UK. The study 
received approval from the local ethics committees at South Birmingham, Birmingham East, 
North, and Solihull, and informed written consent was obtained in accordance with the 
Declaration of Helsinki in all cases. For patients with MGUS/MM, BM aspirates from the iliac 
crest were diluted in MACS buffer for removal of the CD138+ cells using anti-CD138+ 
antibody-linked magnetic beads (Miltenyi Biotech, UK), before the remaining cellular fraction 
was diluted in complete medium, and BMMSCs allowed to adhere to tissue culture plates. 
Control BMMSCs for the transcriptomic study were obtained by flushing out a section of rib 
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from patients undergoing thoracotomies with RPMI1640. Around 80% of the patients 
recruited to this control group had a primary lung tumour: none had bone marrow 
involvement or had received chemotherapy. Patient number and characteristics for the 
transcriptomic study are shown in Supplementary Table 1, while those of the BMMSCs used 
in all other studies are shown in Supplementary Table 2. For the other studies, „healthy‟ 
BMMSCs were isolated from patients undergoing hip surgery, with informed written consent 
obtained and samples collected through the University of Birmingham Research Tissue 
Bank (HTA license 12358, REC reference 09/H1010/75). Bone marrow aspirates from the 
femoral head were diluted in RPMI and the BMMSCs in the non-fatty layer allowed to adhere 
to tissue culture plates. BMMSCs and the HS5 human bone marrow fibroblast cell line 
(ATCC CRL11882, LGC Standards, UK, purchased December 2013, tested for mycoplasma 
every 3 months by PCR) were cultured in RPMI (Sigma, UK) with 10% FBS (Hyclone, UK) at 
37oC in a humidified incubator with 5% CO2. BMMSCs were allowed to adhere and 
proliferate to approximately 80% confluence before harvesting. Wild-type or active site 
mutant PADI2 (C647S), each with N-terminal FLAG tag, were expressed through transient 
transfection of the cDNAs within the pcDNA3 vector (or empty vector control) using jetPEI 
(Polyplus transfection, France) for 24 hours before analysis. Where shown, the pan-PADI 
inhibitor Cl-Amidine (200 µM, Caymen Chemical, USA) was used for 48 or 72 hours. siRNA 
against PADI2 at 20 nM (Oligo 1: AGCCTTGACTCATTTGGAA, and Oligo 4: 
AAGCGAATCACCATCAACA) or PADI4 (GCGAAGACCTGCAGGACAT) were transfected 
using TransIT-TKO (Mirus Bio, USA) and assayed at the timepoint shown. 
Transcriptomic and Real-time PCR analyses 
At passage 3, mRNA from BMMSCs (Supplementary Table 1) was extracted using the 
RNeasy mini kit (Qiagen, Germany). mRNA was prepared and hybridized to Affymetrix 
HuEx-1_0-st-v2 exon arrays (Affymetrix, USA) as per manufacturer‟s instructions. Gene 
level analysis of the Affymetrix exon array was performed using Affymetrix Expression 
Console with the default settings of “Extended: RMA-Sketch” and Affymetrix annotation 
©    2016 Macmillan Publishers Limited. All rights reserved.
8 
 
8 
 
na32. Differentially expressed genes were identified using the limma package(30) with cut-
off values of p < 0.001 and absolute fold change > 1.5. Heatmaps were generated using 
dChip (http://www.dchip.org/) with the default settings. Full dataset is available in the Gene 
Expression Omnibus repository with accession number GSE80608. For Taqman analyses, 
RNA was isolated using the RNeasy kit before reverse transcription (AMV reverse 
transcription kit, Promega, UK). Taqman real-time PCR was performed on an ABI7500; 
using primer/probe mixes (Supplementary Table 3, Life Technologies, UK). Cycle threshold 
was automatically determined by ABI7500 software and expression levels were normalized 
to ACTB and calculated relative to control. All transcript data are presented as median-
centred box and whisker (10-90th percentile) plots. 
Detection of apoptosis by flow cytometry 
Primary BMMSCs from MGUS patients that showed high or low PADI2 protein levels 
(Supplementary Table 2) were seeded at 5x105 cells 24 hours before 106 JJN3 cells were 
added to a TransWell insert (Costar), 24 hours prior to treatment with 10nM bortezomib. 
After a further 24 hours, JJN3 cell apoptosis was assessed by Annexin V/propidium iodide 
staining as per manufacturer‟s instructions (Life Technologies, UK) and flow cytometry 
(LSRII; BD Biosciences). The resulting data were gated and quantified (Flow Jo v.7.6.5) and 
presented after subtraction of background apoptosis of untreated, monocultured JJN3 cells. 
Where shown, BMMSCs were treated with Cl-Amidine (200 µM, 16 hours), which was 
removed before washing and subsequent incubation with JJN3 cells (within the TransWell 
insert). Experiments were performed three times and expression analysed in triplicate; data 
presented as mean ± s.e.m. 
Measurement of IL6 
HS-5 cell culture supernatants were harvested after treatment with either Cl-Amidine or 
siRNA and centrifuged to remove dead cells. Supernatants were analysed using an IL-6 
detection kit as per manufacturer‟s instructions (eBioscience). Experiments were performed 
three times in triplicate; data are presented as mean ± s.d. IL-6 from BM plasma was 
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detected using a multiplex bead analysis approach (Affymetrix, USA). Measurements were 
performed as per manufacturer‟s instructions. Briefly, plasma samples, diluted with an equal 
volume of phosphate-buffered saline, pH7.4, were incubated with monoclonal antibody-
coated capture beads for 1 hour at 20°C. Washed beads were further incubated with biotin-
labelled polyclonal anti-human cytokine antibody for 30 minutes, streptavidin-phycoerythrin 
for 30 minutes and analysed on a Luminex 100 bioanalyser (Luminex) and converted to 
absolute concentrations using standard curves. Data are presented as median-centred box 
and whisker (10-90th percentile) plots. 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation was performed as previously described(31). Briefly, HS5 
fibroblasts were crosslinked with 1% formaldehyde before neutralisation with 0.125 M 
glycine. After lysis (10 mM Tris-HCl, pH8.0, 10 mM NaCl, 0.2% NP40, 10 mM sodium 
butyrate, 50 µg/mL phenylmethylsulfonyl fluoride [PMSF] and 1 µg/mL leupeptin), nuclei 
were purified, lysed (50 mM Tris-HCl, pH8.1, 10 mM EDTA, 1% SDS, 10 mM sodium 
butyrate,  50 µg/mL PMSF and 1µg/mL leupeptin) and diluted in immunoprecipitation (IP) 
buffer (20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.01% SDS, 10 mM 
sodium butyrate,  50 µg/mL PMSF and 1 µg/mL leupeptin). DNA was sheared to 300-1000 
bp, and diluted further in IP buffer. After pre-clearing (normal rabbit IgG), chromatin was co-
immunoprecipitated with anti-histone H3 trimethyl K4 (Abcam, ab8580) or anti-histone H3 
cit26 (Abcam; ab19847, lot GR146412-1). After washing and elution of protein-DNA 
complexes from the beads (100 mM NaHCO3, 1% SDS), cross-links were reversed by 
heating, and treated with proteinase K. DNA was purified; primers used to quantify DNA are 
shown in Supplementary Table 4. Experiments were performed three times and PCR 
performed in triplicate; data presented as mean ± s.e.m. 
Western blotting 
Samples were harvested, washed in PBS and after pelleting, lysed directly in lysis buffer (10 
mM HEPES/KOH pH7.4, 10 mM KCl, 0.05% NP-40, 1 mM sodium orthovanadate). After 
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centrifugation of the lysate, the supernatant containing the cytoplasmic components was 
retained, and the pelleted nuclei were washed with lysis buffer before extraction of the 
nucleoplasmic protein fraction in low salt lysis buffer (10 mM TRIS/HCl pH7.4, 0.2 mM 
MgCl2). After blocking, membranes were probed with antibodies against actin (AC-40; 
Sigma, UK), R26cit (ab19847; Abcam, UK), R2,8,17cit (ab5103; Abcam, UK), PADI2 
(ab19847; Abcam, UK) or PADI4 (ab128086;  Abcam, UK), followed by the appropriate 
HRP-linked secondary antibody (Cell Signalling, NEB, UK), and visualised using ECL Prime 
(GE Healthcare).  
Statistics 
Sample size for patient studies could not be pre-determined due to lack of similar data on 
healthy and MGUS populations. No samples were excluded from analyses presented. Error 
bars are shown for all data presented. All statistics were performed using GraphPad Prism 
v.6.07. In order to compare different patient groups without assumptions of data distribution, 
non-parametric tests were used (Mann-Whitney and Kruskal Wallis) with Dunn‟s post-test 
comparisons where appropriate. Where statistical tests were used on data from cell culture 
experiments, student‟s 2-tailed t-tests with Welch‟s correction were used to avoid 
assumptions of variance between groups. 
Results 
There is strong evidence to suggest that BMMSCs from patients with MM show a 
transformed phenotype: supporting malignant plasma cell survival, proliferation, and evasion 
of chemotherapy-mediated cell death(7-11). The BMMSC phenotype in MGUS patients is 
less-well characterised(7). We therefore performed a transcriptomic analysis of mRNA 
extracted from BMMSCs cultured from controls, MGUS and MM patients. BMMSCs isolated 
from patients with both MGUS and MM show markedly different gene expression profiles 
compared to the controls (Figure 1, cut-offs used, p<0.001, fold change 2.0), consistent with 
the previous report(7). Although a large number of transcripts were found to be differentially 
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expressed between controls and MGUS (91) or MM (117; cut-off p<0.001, fold change of 
>2.0; Supplementary Tables 5 and 6), none were found to vary between MGUS and MM 
using the same statistical cut-offs, and only 32 if these were relaxed (cut-off of p<0.01, fold 
change of >1.3; Supplementary Table 7). Pathway analysis of differentially expressed genes 
between disease and control groups demonstrated that the most prominent enriched 
signalling pathway was WNT (p=0.00012 and 0.00002 for MM vs control and MGUS vs 
control, respectively; Supplementary Tables 8 and 9 and Supplementary Figure 1a), which 
has been previously implicated in the pathogenesis of MM(32-34). In addition, within the top 
five upregulated transcripts in MGUS and MM was a member of the PADI family of enzymes, 
PADI2 (Figure 2a), which was up-regulated over 5-fold in both MGUS and MM patient 
BMMSCs. Importantly, two other functionally related transcripts were also in the top five; 
filaggrin, a well-described target of PADI2 (Figure 2b), and SLC14A1, which encodes the 
urea transporter required for excretion of ammonium produced through PADI2 activity 
(Figure 2c, Supplementary Figure 1b). Interestingly, we recently published evidence that 
urea concentrations are significantly increased in the bone marrow plasma of patients with 
both MGUS and MM, consistent with significantly increased cellular production of 
ammonium, perhaps through PADI2 activity, in the bone marrow niche(35). 
To confirm the increased expression of PADI2 in BMMSCs in MGUS and MM, we assessed 
both mRNA and protein expression in BMMSCs isolated from an independent cohort of 
healthy individuals, MGUS and MM patients (Supplementary Table 2). We found that mRNA 
expression of PADI2 was relatively low in BMMSCs from healthy patients (Figure 2d), 
corresponding with an almost undetectable protein expression (Figure 2e). However, in 
BMMSCs from MGUS or MM patients, expression of PADI was greatly increased (Figure 2d 
and e): indeed mRNA expression was increased greater than 30-fold. Corresponding mRNA 
expression of other PADI family members was unchanged (Supplementary Figure 2). We 
therefore assessed the activity of PADI2 through its citrullination of a recently described 
target: histone H3R26cit(27). We found that this modification of histone H3 was significantly 
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increased in BMMSCs from MGUS and MM compared to healthy individuals (Figure 2e), 
where it was almost universally absent. In contrast, citrullination of other arginine residues in 
histone H3 that represent more specific PADI4 targets (R2, R8 and R17) were not 
upregulated to the same extent, suggesting that PADI2 activity, rather PADI4 was likely to be 
responsible for H3R26cit levels observed. 
BMMSCs have been shown to play an important role in the support of malignant plasma cell 
survival, proliferation and resistance to chemotherapy(36). We therefore hypothesised that 
increased expression of PADI2 may alter the ability of the BMMSC to perform this function. 
We had previously noted that within the primary BMMSCs we isolated from MGUS and MM 
patients, some had relatively low expression of PADI2 while others were higher. We 
therefore selected two lines each of „low‟ and „high‟ expressers (Figure 2e, MGUS samples 2 
and 5 [low] or 3 and 4 [high], Supplementary Table 2), and co-cultured these with JJN3 cells 
using a TransWell system for 24 hours before treatment with the clinically relevant 
chemotherapeutic agent, bortezomib. Although physically separate, the two cell lines could 
interact through metabolic or secreted factor interactions. We found that although co-culture 
with low PADI2-expressing BMMSCs had little effect on JJN3 cell viability after bortezomib 
treatment, high PADI2-expressing resulted in a significant protection, reducing the cell death 
induced by about 75% (Figure 3a). Interestingly, pre-incubating the high PADI2-expressing 
BMMSCs with the pan-PADI inhibitor Cl-Amidine before co-culture with JJN3 cells led to a 
significant increase in bortezomib-induced apoptosis of the JJN3 cells (Figure 3b). These 
data overall suggested that at least part of the protection from chemotherapy-induced 
apoptosis elicited by BMMSCs was through a PADI2-mediated event. It had previously been 
shown that IL-6 production in the bone marrow microenvironment is important for the 
acquisition of resistance phenotypes by the plasma cells(20, 37, 38), with evidence for a role 
in bortezomib-induced resistance(39). We therefore investigated IL-6 expression by 
BMMSCs, and observed significant increased transcription of IL-6 mRNA (Figure 3c), which 
led to enhanced secretion into the medium from primary cells from MGUS and MM (Figure 
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3d). In addition, when mRNA expression of IL-6 was plotted against that of PADI2, we found 
that they were positively correlated (Figure 3e), providing further evidence for a mechanistic 
link between these two factors in MGUS and MM. 
Using an immortalised, non-transformed BMMSC line (HS5), we assessed the effect of 
siRNA-mediated reduction in PADI2 expression (Figure 4a) on the expression of IL-6, as 
well as other factors expressed by BMMSCs known to play a role in MM pathogenesis: 
CXCL12 and cMET. We found that expression of all three pro-malignant factors was 
decreased when PADI2 expression was also reduced, or PADI activity was inhibited by Cl-
Amidine (Figure 4b). Importantly, siRNA of PADI4 (Figure 4a) did not affect expression of 
any of these factors, showing that this effect was specifically through modulation of PADI2 
expression (Figure 4b). Expression of another important factor in the pathogenesis of MM, 
vascular endothelial growth factor (VEGF), was not found to be modulated by PADI2 or 
PADI4 expression (Supplementary Figure 3). We directly tested the effect of knocking down 
or inhibiting PADI2 on IL-6 secretion into the medium of HS5 cells through siRNA or Cl-
Amidine treatment, and found that IL-6 was reduced in both conditions, and not further 
reduced by combining both siRNA and inhibitor (Figure 4c), further supporting our findings 
that PADI2 is the main PADI family member that regulates IL-6 expression in BMMSCs.  
Finally, we over-expressed PADI2 and found that IL-6 mRNA expression was increased 10-
fold (Figure 4d), whereas expression of an active-site mutant of PADI2 C647S(40) had no 
effect (Figure 4d). These data therefore provide direct mechanistic link between the 
expression of PADI2 and increased IL-6 production in BMMSCs from MGUS/MM patients. 
It has previously been shown that PADI2 activity can citrullinate the R26 residue of histone 
H3 (H3R26cit), resulting in increased transcription of a number of genes(27). Our data also 
showed increased levels of this modification in BMMSCs from MGUS and MM (Figure 2e). 
We therefore hypothesised that the mechanism by which PADI2 activity could modulate 
transcription from the IL-6 locus was through increasing citrullination of H3R26 in its 
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promoter. Primer pairs that covered the IL-6 promoter region were designed (Figure 5a), and 
a chromatin immunoprecipitation experiment performed, in which after either siPADI2 or Cl-
Amidine treatment, antibodies against H3R26cit and trimethylated K4 of histone H3 
(H3K4me3) were used to pull down chromatin associated with these modifications. 
H3K4me3, a modification associated with active areas of chromatin, was used as a positive 
control to determine whether changes in expression altered the overall activation state of the 
chromatin. We found that both Cl-Amidine (Figure 5b) and siPADI2 (Figure 5d) decreased 
the enrichment of H3R26cit in the IL-6 promoter region, the effects of which were particularly 
pronounced at and downstream of the transcription start site (TSS; Figure 5a). This 
correlated with a loss of the activating histone mark, H3K4me3 in the same conditions (Cl-
Amidine; Figure 5c, siPADI2; Figure 5e), indicating reduced activation of the IL-6 promoter 
locus as a result of reduced PADI2 activity. 
Our data therefore show that PADI2 expression correlates with IL-6 expression in primary 
BMMSCs from patients with MGUS and MM (Figure 3) as well as citrullination of the H3R26 
(Figure 2e) in the same cells. In addition, we have shown that PADI2 expression can directly 
increase IL-6 expression (Figure 4) through citrullination of the R26 residue of histone H3 in 
the promoter region of the gene (Figure 5). Finally, we show that PADI2 expression and 
activity in BMMSCs can modulate malignant plasma cell resistance to the chemotherapeutic 
agent, bortezomib (Figure 3a&b, and Figure 6). 
 
Discussion 
MM is an incurable disease that arises from the pre-malignant condition MGUS, present in 
the bone marrow of up to 7.5% of the elderly population(1, 41, 42). With increasing life 
expectancies and the resulting shift in the demographics of most developed countries, this 
disease represents a significant clinical challenge. Although it is now clear that the BM 
microenvironment is transformed in patients with MM, there are little data concerning the 
©    2016 Macmillan Publishers Limited. All rights reserved.
15 
 
15 
 
nature of the MGUS microenvironment. We demonstrate here that BMMSCs from patients 
with both MGUS and MM have a transformed transcriptome compared to those from healthy 
individuals, in agreement with previous results(7). Our data, alongside those of others and 
our previous metabolomic study(35) highlight the significant similarities between the 
microenvironment of the BM in MGUS and MM, suggesting that transformation of the BM 
microenvironment is an early event in disease aetiology, raising the potential of interfering 
with this process in order to delay or prevent progression of patients with MGUS to MM. In 
addition, these data further highlight a need to identify those biological determinants in the 
BM that actually contribute to the progression of this disease: whether these are active 
drivers, or release of inhibitors of malignant progression.  
Our data provide a mechanism by which IL-6 secretion is increased in BMMSCs of patients, 
which may contribute to treatment failure of bortezomib, a key therapeutic agent in MM 
treatment strategies. It is important to note, however, that anti-IL-6 therapy has not proven to 
be an efficacious agent in MM thus far, suggesting that targeting this signalling axis alone is 
likely to be insufficient to achieve clinical benefit(43). PADI2 may therefore represent a novel 
upstream target, as our data suggest that its activity increases expression of other central 
signalling networks between BMMSCs and myeloma cells, such as HGF-cMET and 
CXCL12-CXCR4 (Figure 4b). PADIs are a family of enzymes, of which PADI2 is becoming 
increasingly linked to a number of chronic diseases, including cancer(27, 44), rheumatoid 
arthritis(45), Alzheimer‟s disease(46) as well as autoimmune disease(47). Targets of the 
PADI enzymes include proteins with diverse functions such as extracellular matrix formation 
(e.g. vimentin and myelin) and chromatin structure (histone H3)(24). Importantly, as arginine 
citrullination is expected to be a relatively long-lived post-translational modification due to the 
absence of a characterised peptidylcitrullinine iminotransferase, these modifications may 
only be reversed through protein turnover. In the case of histone H3R26 citrullination within 
the IL-6 promoter, this suggests that the chromatin unwinding and activation induced by this 
modification may only be reversed through proliferation or histone eviction. It is also highly 
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likely that a much larger number of pro-malignant transcripts are also modulated by the 
activity of PADI2. Indeed, a previous study of the effect of PADI2 on oestrogen receptor-
mediated transcriptional regulation showed that it regulated over 200 transcripts in those 
conditions(27). Future work will focus on defining more of these targets in BMMSCs in order 
to determine the broader implications of PADI2 in the transformation of the healthy BM to 
that of MGUS/MM. 
Therapeutic targeting of PADI2 may therefore represent a good (and early) therapeutic 
target in MGUS patients as well as those with MM, which may act by removing a significant 
proportion of the supportive signalling required by malignant plasma cells for survival and 
proliferation. Indeed, with the growing role for PADI2 in other chronic diseases, this enzyme 
may represent a novel therapeutic target in many pathological conditions. 
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Figure Legends 
Figure 1: Heatmap of transcriptomic analysis from thirty BMMSC samples, 10 each from 
control, MGUS and MM patients shows that cells from patients with MGUS and MM cluster 
together, and are different from those isolated from healthy individuals. 74 genes were 
identified with a cut-off for gene expression change of >2.0 fold, and p<0.001. 
Figure 2a: Three of the top five upregulated transcripts that differed between control and 
„disease‟ (MGUS/MM) BMMSCs identified from the transcriptomic analysis were the peptidyl 
arginine deiminase, PADI2 (a), filaggrin (b) and the urea transporter, SLC14A1 (c). d: PADI2 
mRNA expression in BMMSCs from controls, MGUS and MM patients compared to beta-
actin, analysed using Taqman, plotted on a logarithmic scale. Significant changes shown 
were calculated using Mann-Whitney tests. „*‟; p<0.05, „**‟; p<0.005, „****‟; p<0.0001. e: 
BMMSCs derived from patients with MGUS and MM have greatly increased expression of 
PADI2 and citrullination of histone H3 on residue R26 (R26cit) compared to healthy controls. 
Citrullination of other arginine residues on histone H3 (R2,8,17) under the control of PADI4 
are not similarly consistently increased. „CL‟ and „CH‟ indicate control samples (CL: low 
expressing, CH: high expressing) analysed on each blot in order for blots to be more easily 
compared. 
Figure 3a: Expression of PADI2 protects plasma cells from chemotherapy-induced 
apoptosis. JJN3 cell apoptosis as a percentage of total cells, either untreated („JJN3‟), or 24 
hours after treatment with 10 nM bortezomib („+BTM‟). When co-cultured with either a low 
PADI2-expressing („PADI2 low‟) or high PADI2-expressing („PADI2 High‟) BMMSCs across a 
Boyden chamber, JJN3 cells are partially protected from bortezomib-induced apoptosis, with 
extent of protection correlating with PADI2 expression. Two primary BMMSC lines were 
used per assay, each repeated n=3. Data were analysed by Kruskal-Wallis test (p<0.0001), 
with Dunn‟s multiple comparisons test to test for those values that were significantly 
different. Error bars show standard deviation. b: Inhibition of total PADI activity in the PADI2 
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High expressing lines using the pharmacological inhibitor, Cl-Amidine („CL‟) significantly 
reduces acquired protection from bortezomib. Data were analysed using Mann-Whitney test, 
error bars show standard deviation. „**‟; p=0.002 c: IL-6 expression is significantly increased 
in BMMSCs derived from patients with MGUS and MM compared to controls. IL-6 mRNA 
expression was normalised to beta-actin. Significant changes shown between groups were 
calculated using Mann-Whitney tests. „****‟; p<0.0001. Error bars are d: Bone marrow 
concentrations of IL-6 are also increased in patients with MGUS and MM. Mann-Whitney 
tests were again used to calculate significance of differences between groups. „***‟; 
p=0.0005, „****‟; p<0.0001 e: Scatterplot of the expression of  PADI2 against IL-6 as 
measured in BMMSCs from 38 patients with MM and MGUS shows that their expression is 
highly correlated (r2 = 0.540, non-linear fit).  
Figure 4a: Confirmation of knockdown by siPADI2 by two independent siRNA sequences.  
b: The expression of the BMMSC component of critical chemokine signalling axes in 
myeloma (IL-6, CXCL12 and cMET) is modulated by PADI2 expression in the immortalised 
BMMSC cell line, HS5. Expression of all three transcripts are reduced in response to 
reduction in PADI2 expression (siPADI2), or the addition of the pan-PADI inhibitor, Cl-
Amidine (200 µM, 72 hours). However, siPADI4 does not alter expression of any of the 
transcripts. c: IL-6 expression, as measured through its secretion into the tissue culture 
medium by the HS5 cell line, is reduced after treatment with Cl-Amidine and/or siPADI2. 
Data shown are mean of n=3 ± standard deviation. p=0.039, unpaired student‟s t-test with 
Welch‟s correction. d: Over-expression of PADI2 increases IL-6 expression, whilst the 
catalytic mutant, C645S, does not increase expression over basal levels. Data shown are 
mean of n=3 ± standard deviation. p=0.004, unpaired student‟s t-test with Welch‟s 
correction.  
Figure 5a: Diagram showing the coverage of the IL-6 promoter region by the primer pairs 
used in the chromatin immunoprecipitation analysis. Pull-down of chromatin  associated with 
either citrullinated R26 (b and d) or trimethylated K4 (c and e) of histone H3, show that both 
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inhibition of PADI activity by Cl-Amidine (b and c) and reduction of PADI2 expression 
(through siRNA, d and e) reduce the enrichment of these marks on and downstream of the 
IL-6 transcription start site, indicating that PADI2 activity is required for full activation of 
transcription from this locus. 
Figure 6: Model of how PADI2 activity in BMMSCs directly contributes to malignant plasma 
cell phenotype in patients with MGUS and MM. PADI2 citrullinates histone H3 at residue 
R26 within the promoter region of the IL-6 gene, which increases its expression and 
secretion. IL-6 can then mediates its effects on other cells within the bone marrow, including 
the malignant plasma cells, which become more resistant to chemotherapeutic agents, such 
as Bortezomib. 
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